Hangzhou Adcoris Biopharmacy — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

A biopharma firm creating novel biologic drugs for cancer and immune disorders.

OncologyImmunology

An integrated antibody discovery platform combining hybridoma and display technologies for rapid generation of lead candidates.

Potential to address niche targets or combinations overlooked by larger players in the oncology-immunology space.

Risk of failing to advance a candidate to clinical proof-of-concept due to scientific or resource constraints.

Operates in a segment with many similar early-stage biotechs, competing for funding, talent, and partnership attention.